The shift from austerity to fiscal spending matters, even if the short - term growth implications will be limited.
Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®;
austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated
shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results
from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data
from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified
from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
As well, Flaherty cut in half an Employment Insurance premium hike scheduled for Jan. 1, a move that will cost Ottawa $ 600 million a year, but will leave that cash in the pockets of workers and companies — a
shift from deficit - shrinking
austerity to stimulus.
Markets were thrown into a tailspin Monday after weekend elections in France and Greece led to a sharp
shift in the political landscape with the focus
shifting away
from austerity.
From New York City's bankruptcy to Puerto Rico's insolvency and Third World debtors subjected to IMF «
austerity programs,» national bankruptcies
shift control to centralized financial planners in what Naomi Klein has called Crisis Capitalism.
For Jackson and McClymont,
shifting the discourse away
from «
austerity» and public spending reductions will mean Labour can fight the election on their terms.
It is vital that the momentum to introduce a mansion tax is kept up, in order to
shift the burden of
austerity from the poor to the wealthy.
Greeks have witnessed discussions
shift from $ 1 billion in additional measures (last proposal put forth by the New Democracy - PASOK government following demands
from creditors), to over $ 10 billion in additional measures last month, to today's «Greekment» according to which Greece will undergo harsher
austerity (for next three years) than at any other point since the crisis began.
A year on
from the emergency budget and spending review it is becoming abundantly clear that public opinion has slowly
shifted, both in Britain and Europe towards an opposition to
austerity and an alternative vision for society.
From a different angle, however, the approach may be seen as a stand by the courts against a politically driven tide, prefacing a
shift of approach generally as we face post-election
austerities.